<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Ni X</submitter><funding>Chinese Academy of Sciences</funding><funding>Research Grants Council of the Hong Kong Special Administrative Region, China</funding><funding>Hong Kong Polytechnic University</funding><funding>National Natural Science Foundation of China</funding><pagination>gkaf888</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12445692</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>53(17)</volume><pubmed_abstract>Small-molecule intervention and stabilization of G-quadruplexes (G4s) have been investigated for the potential as therapeutic approaches. MYC plays diverse roles in cellular functions, making it a highly desirable yet challenging target. One promising strategy includes DNA G4 structures, which mediate transcriptional control over MYC in the presence of small-molecule ligands. Unraveling the effects of these ligands on G4 stability and functionality is seldom achieved yet essential for designing potent ligands against these intractable targets. This study introduces BTO-28, a benzothiazole-based ligand that binds with high affinity to the MYC G4. In vitro experiments, NMR analysis, and intracellular assays collectively indicate that BTO-28 potentially downregulates MYC transcription through a G4-mediated mechanism. Structural determination of the 2:1 benzothiazole-MYC G4 complex provides insights into unexpected molecular interactions, highlighting for the first time a unique hydrogen-bonding pattern involving the nucleobase surrogate and flanking residues. The protonated pyrrolidine side chains of BTO-28 reorient to form hydrogen bonding with the external G-tetrad, establishing a previously uncharacterized ligand-G4 interface. This work advances the rational design of G4-binding ligands and clarifies the molecular basis underlying MYC recognition.</pubmed_abstract><journal>Nucleic acids research</journal><pubmed_title>Molecular recognition and effects of a benzothiazole derivative targeting the MYC G-quadruplex.</pubmed_title><pmcid>PMC12445692</pmcid><funding_grant_id>15300522</funding_grant_id><funding_grant_id>XDB1060000</funding_grant_id><funding_grant_id>22177127</funding_grant_id><funding_grant_id>22174155</funding_grant_id><pubmed_authors>Wong WL</pubmed_authors><pubmed_authors>Hu XD</pubmed_authors><pubmed_authors>Long W</pubmed_authors><pubmed_authors>Ni X</pubmed_authors><pubmed_authors>Wang C</pubmed_authors><pubmed_authors>Cao C</pubmed_authors><pubmed_authors>Lan W</pubmed_authors></additional><is_claimable>false</is_claimable><name>Molecular recognition and effects of a benzothiazole derivative targeting the MYC G-quadruplex.</name><description>Small-molecule intervention and stabilization of G-quadruplexes (G4s) have been investigated for the potential as therapeutic approaches. MYC plays diverse roles in cellular functions, making it a highly desirable yet challenging target. One promising strategy includes DNA G4 structures, which mediate transcriptional control over MYC in the presence of small-molecule ligands. Unraveling the effects of these ligands on G4 stability and functionality is seldom achieved yet essential for designing potent ligands against these intractable targets. This study introduces BTO-28, a benzothiazole-based ligand that binds with high affinity to the MYC G4. In vitro experiments, NMR analysis, and intracellular assays collectively indicate that BTO-28 potentially downregulates MYC transcription through a G4-mediated mechanism. Structural determination of the 2:1 benzothiazole-MYC G4 complex provides insights into unexpected molecular interactions, highlighting for the first time a unique hydrogen-bonding pattern involving the nucleobase surrogate and flanking residues. The protonated pyrrolidine side chains of BTO-28 reorient to form hydrogen bonding with the external G-tetrad, establishing a previously uncharacterized ligand-G4 interface. This work advances the rational design of G4-binding ligands and clarifies the molecular basis underlying MYC recognition.</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Sep</publication><modification>2026-06-03T16:58:52.791Z</modification><creation>2026-04-29T03:12:45.349Z</creation></dates><accession>S-EPMC12445692</accession><cross_references><pubmed>40966493</pubmed><doi>10.1093/nar/gkaf888</doi></cross_references></HashMap>